Endava Plc Form 6-K Summary
Business Context and Reporting Period
This Form 6-K filing by Endava Plc, dated December 14, 2021, reports the results of the Company's Annual General Meeting (AGM) held on December 9, 2021. The filing confirms that all resolutions proposed by the Board of Directors were duly passed by shareholders.
Key Financial Metrics
The filing text does not provide specific financial metrics such as revenue, profit, cash flow, margins, debt, or liquidity. This document focuses exclusively on corporate governance outcomes and voting results rather than financial performance data.
Material Changes
No material financial changes are reported in this filing. The primary outcome is the successful ratification of the 2021 Annual Report and Accounts and the re-election of the Board of Directors.
Guidance, Outlook, and Governance Results
The AGM results indicate strong shareholder support for the Company's direction and leadership:
- Annual Accounts: The 2021 Annual Report and Accounts were adopted with 99.97% of votes in favor.
- Auditor Re-appointment: KPMG LLP was re-appointed as auditors with 99.999% of votes in favor.
- Director Re-elections: All nine directors standing for re-election were approved, with vote percentages ranging from 98.84% to 99.99%.
- Remuneration Report: The Directors' remuneration report was approved with 95.93% of votes in favor.
The filing incorporates by reference several registration statements (Forms S-8 and F-3) but does not contain new management commentary, risk factors, or forward-looking guidance within this specific text.
Investor Verification Checklist
- Verify the full text of the 2021 Annual Report and Accounts referenced in Resolution 1 for detailed financial performance.
- Review the Notice of Annual General Meeting on the Company's investor website for the full text of resolutions.
- Confirm the specific remuneration details for Directors as outlined in pages 76 to 97 of the 2021 Annual Report.
- Check the referenced SEC registration statements (File Nos. 333-228717, 333-248904, 333-259900, 333-229213) for details on equity compensation plans.